资讯

Revelation Biosciences Announces Special Webcast to Review Positive Top-line Clinical Data

Gemini normalized the inflammatory response at the cellular level in stage 3 and 4 CKD patients – – Gemini could potentially ...
Business Wire3月

Revelation Biosciences, Inc. Announces Closing of $4 Million Public Offering

SAN DIEGO--(BUSINESS WIRE)--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize ...
Yahoo Finance3月

Revelation Biosciences, Inc. Announces Closing of $4 Million Public Offering

SAN DIEGO, May 29, 2025--(BUSINESS WIRE)--Revelation Biosciences, Inc. (NASDAQ: REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing ...
Business Wire3月

Revelation Biosciences, Inc. Announces Pricing of $4 Million Public Offering

SAN DIEGO--(BUSINESS WIRE)--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize ...
Investing3月

Revelation Biosciences sets terms for $4 million public offering

Revelation Biosciences is developing Gemini, a proprietary formulation aimed at preventing and treating diseases by modulating trained immunity. The company is currently evaluating Gemini for various ...
dbta4 年

Revelation Software Releases Latest Patch for OpenInsight 9.4

Revelation is releasing a “Roll Up” patch to OpenInsight version 9.4 that will enhance debug functionalities and improve operations. This patch was made as a result of user reports and suggestions, ...